| |
|
|
|
Health Network Communications, Millennium Gloucester Hotel, London, United Kingdom
7th - 10th December 2010
Pre-conference workshop: Tuesday 7 December 2010
HTA uptake and impact
Objectives:
This interactive session will provide attendees with a review of the uptake of HTA and strategies and requirements for integration into product development.
09.00 Registration and coffee
Your workshop leader
Louise Perrault
Principal Consultant International Market Access Consulting GmbH Louise Perrault is a senior executive with expertise in International Market Access in Europe, UK, Canada, and Australia. She has over 22 years experience in the pharmaceutical sector serving in various roles within major pharma, the biotech industry, and consulting firms. She has diverse experience ranging from sales to health economics and reimbursement, combined with a strong understanding of clinical drug development. Further, with experience spanning both regional and global activities, she provides an overall strategic approach while remaining pragmatic and focused on the deliverables.
09.30 Overview and introduction
- Health Economic approaches in theory and practice
10.30 Morning refreshments
11.00 Strategy development
- Establishing a products value potential
- Value assessment / decision tools from early to late phase
- Value of patient reported outcomes
14.00 Value dossier submissions - Development of dossiers including key messages and supporting evidence
- Adapting market access approaches to different HTA across Europe
- Creating value presentations for payers
15.00 Afternoon refreshments and close of workshop
Day One, Wednesday 8 December 2010
08.00 Registration and coffee
08.50 Opening remarks from the chair
Mel Walker, Director Global Integrated Payer Strategy, GlaxoSmithKline, United Kingdom
09.00 Industry policies in relation to Health Technology Assessment - The research-based industry is committed to show the added value of new medicines. Who is the best arbiter of that added value?
- Need for good governance and stakeholder inclusion in HTA and pricing & reimbursement decisions
- The broad perspective: how to allocate resources in health care?
- A challenge: managing uncertainty and fostering dialogue and flexibility throughout the lifecycle of a product
Richard Bergström, Direcotir General Co-Chair, LIF Sweden EFPIA's HTA Task Force, Sweden
09.30 European network for Health Technology Assessment Joint Action (EUnetHTA JA)
- Background, focus of current activities
- Organisation and management
- Stakeholder involvement
Julia Chamova, Secretariat Manager, EUnetHTA, Denmark
10.00 Industry perspective of European Cooperation on HTA
- Key policy developments over the last 12 months
- Assessing value in healthcare
- Industry perspective
Andrea Rappagliosi, Vice President, European Government Affairs & Head of Brussels Office, GlaxoSmithKline, Belgium
10.30 Speed networking and morning refreshments
COOPERATION BETWEEN REGULATORY AGENCIES AND HTA’s11.15 Emerging interface between regulators and HTA bodies - Advantages and disadvantages of greater collaboration between regulators and HTA bodies
- Areas where regulators and HTA bodies can and should collaborate
- Parallel scientific advice between regulators and HTA bodies
Dr Ian Hudson, Director of Licensing, MHRA, United Kingdom
11.45 Communicating health economic evidence to payers
- Health economists struggle to make their evidence understandable
- How can you optimally present economic evidence to payers?
- How can you effectively distribute economic evidence in your organization?
- Case study on how health economic evidence can be easily distributed and clearly communicated using an interactive presentation platform on the web
Gijs Hubben, Chief Executive Officer, BaseCase Software, Germany 13.15 Latest developments in HTA policy in England and Wales - Highlights of the updated technology appraisal
- A new evaluation pathway for medical technologies
- Challenges for the technology appraisal programme
Dr Carole Longson, Head of Health Technology Assessment, National Institute for Health and Clinical Excellence, United Kingdom
13.45 HTA in Ireland
- National HTA Framework
- HTA to inform national policy
- Rapid HTA
- HTA to inform local decision making
Dr Máirín Ryan, Director of Health Technology Assessment, Health Inforamtion and Quality Authority (HIQA), Ireland
14.15 HTA in the Netherlands - Assessment and appraisal of costly innovative drugs
- Innovative health care technologies
- Coverage with evidence development in the Netherlands
Dr Gepke Delwel, Senior policy Advisor, Dutch Healthcare Insurance Board (CVZ), The Netherlands
14.45 HTA in France
- The stakeholders
- HTA maximisation strategies
- Economic evaluation
Dr François Meyer, Director, Health Technology Assessment Division, Haute Autorit� de Sant�, France
15.15 Afternoon Refreshments
15.45 Value of innovation from an HTA Agency perspective: proposals and limitations - Health system overview and regulatory framework
- Development of guidelines to improve the process of decision making
Oriol Solà-Morales, HTA Director, CAHTA, Spain
16.15 HTA in Poland
- Rise of HTA and the frame work for HTA in Poland
- Assessments and appraisals in Poland
- Future challenges, limitations and opportunities for appraisal programme
Iga Lipska, Director, Agency for Health Technology Assessment - AHTAPol, Poland
16.45 HTA in Italy
- Policy trends in the Italian healthcare system
- Access to medicines in Italy under the NHS
- HTA implementation
Dr Pietro Folino Gallo, Director, AIFA, Italy, Italy
17.15 HTA in Germany
- Examining the new evaluation system, how is it different and what does it hope to achieve
- Understanding the main decision making criteria
- Recent results of IQWiQ evaluations
Dr Peter Kolominsky-Rabas, Director, Interdisciplinary Centre for Health Technology Assessment (HTA) and Public Health (IZPH), University of Erlangen-Nurnberg, Germany
17.45 Closing remarks from the chair
17.50 End of day one and networking drinks reception
Day Two, Thursday 9 December 2010
08.00 Registration and coffee
08.50 Opening remarks from the chair
09.00 HTA in America
- HTA and Comparative Effectiveness Research in the US
- Evolving methods for HTA and CER
- New evidence opportunities in HTA in the wake of ARRA
Jean R. Slutsky, Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, United States
09.30 Effective use of electronic healthcare data for real world evidence development in the US
- Experience with using electronic claims data to support health plan decision-making in medical policy and formulary development: Early results from WellPoint, a large US insurer
- Discerning between a research data environment and a simple database
- Effective dissemination of research findings to better impact patient care
Marcus D. Wilson, President, HealthCore, United States
10.00 HTA in Japan and Asian countries
- Healthcare and health determinants
- Rise and fall of HTA in Japan
- Cost containment and no exit
- Rapid diffusion of HTA framework in Asian countries
- Fragile infrastructure of HTA and future challenges in Asia
Dr Akinori Hisashige, Director, Institute of HTA, Japan, Japan
10.30 Morning refreshments
BEST PRACTICE CASE STUDIES11.00 Relative effectiveness assessment of pharmaceuticals - Why do we need relative effectiveness assessment of pharmaceuticals?
- What is the importance of a common European methodology for relative effectiveness assessment of pharmaceuticals;
- HTA and relative effectiveness assessment; what's in a
name?
Dr Wim Goettsch, Deputy Secretary Medicinal Products Reimbursement Committee, Dutch Healthcare Insurance Board (CVZ), The Netherlands
11.30 Implications for pharma with governmental cost containment plans
- What are the implications of the recession on pricing and reimbursement environment?
- How has health technology assessment become a critical element in cost containment?
- What are the implications on innovation?
Dr Ansgar Hebborn, Head - Global Payer & HTA Program Policy, F.Hoffmann-La Roche Ltd, Switzerland
12.00 Market access approaches to different HTA requirements internationally
- Difference in the use of HTA tool globally
- Horizon scanning and its use to drive collaboration
- PROs and health Economic approaches in theory and practice
Stephen McDonough, Senior Director Health Technology Assessment and Early Portfolio, UCB Pharma, Belgium 13.30 The innovation challenge – what is real innovation? - What is innovation and how do we value it?
- How do payers value innovation?
- How is innovation measured or valued in other industries – are there lessons for Pharma?
- What needs to change?
Janice Haigh, Senior Director, Pricing and Market Access Europe, Astellas Pharma, United Kingdom
14.00 Patient involvement in HTA
- Current and future patient involvement in HTA
- Does patient involvement improve scientific quality, feasibility, or practicality of the proposal
Mary Baker, President, European Federation of Neurological Associations, United Kingdom 14.30 MS drug risk sharing scheme - The pressures that lead to developing patient access schemes - Presentation on the typology for access schemes
- Review evidence for the success or otherwise of access schemes
- Highlight the key risks to healthcare systems of patient access schemes
Professor Christopher McCabe, Chair Health Economics, University of Leeds, United Kingdom
15.30 Risk-sharing scheme do these benefits patients?
- Do these schemes benefit patients
- Ensuring that people have equity of access to the right drug at the right time
Simon Gillespie, Chief Executive Officer, MS Society, United Kingdom
16.00 Risk sharing schemes - beneficial for all parties
- Goverance of pharmaceutical expediture
- Experiences with risk sharing and conditional reimbursement
Dr Filippo de Braud, Director, Clinical Pharmacology and New Drug Development Unit, European Institute of Oncology, Italy
16.30 Closing remarks from the chair
Post-conference workshop: Friday 10 December 2010
Risk sharing and alternative payment schemesOutline: Healthcare providers are facing the financial challenge of funding new, innovative and expensive
medicines for populations who are living longer and demanding better care. This funding dynamic has increased immediate financial pressures on healthcare systems and raised the level of risk associated with uncertainty around both clinical efficacy and budgetary impact. To address this, payers are considering market access hurdles and cost containment measures. In response, the industry should be carefully considering their pricing and reimbursement strategies. How the industry responds to this trend will significantly shape the future.
Objectives: Attendees will increase their awareness of current risk sharing agreements and variations of how those agreements are taking shape across markets.
Attendees will also gain a better understanding of when risk-sharing agreements are appropriate and what steps can be taken to avoid the necessity of alterative payment schemes.
09.30 What’s at risk?
- Reasons behind risk sharing and alternative payment schemes
- Examples of current risk sharing agreements
10.30 Morning refreshments
11.00 How to structure risk
- Payers’ perspective of risk
- How to best address those risks
13.00 Is risk sharing always necessary?
- How to better build value around new therapies
14.00 Afternoon refreshments
15.00 Case Study, Interactive session and Q&A session with discussion
About your workshop leader:
Keiron Sparrowhawk Partner PriceSpective PriceSpective is a value strategy consultancy. Reflective of PriceSpective hands on approach by senior team members, Keiron has lead over 100 projects across a wide range of therapy and policy areas. He has over 34 years of industry and consulting experience and is recognized as a global expert in drug pricing, reimbursement and market access.
Keiron will be joined by Catherine Bolton, Vice President, PriceSpective and Daniele Bruni, Senior Consultant, PriceSpective.
|
|
|
|
|
|
|
|
Organized by:
|
|
Health Network Communications |
|
|
Invited Speakers:
|
|
President, European Federation of Neurological Associations, United Kingdom Direcotir General Co-Chair, LIF Sweden EFPIA's HTA Task Force, Sweden Secretariat Manager, EUnetHTA, Denmark Marcus D. Wilson, President, HealthCore, United States Director, Clinical Pharmacology and New Drug Development Unit, European Institute of Oncology, Italy Senior policy Advisor, Dutch Healthcare Insurance Board (CVZ), The Netherlands Director, AIFA, Italy, Italy Simon Gillespie, Chief Executive Officer, MS Society, United Kingdom Deputy Secretary Medicinal Products Reimbursement Committee, Dutch Healthcare Insurance Board (CVZ), The Netherlands Senior Director, Pricing and Market Access Europe, Astellas Pharma, United Kingdom Dr Ansgar Hebborn, Head - Global Payer & HTA Program Policy, F.Hoffmann-La Roche Ltd, Switzerland Director, Institute of HTA, Japan, Japan Chief Executive Officer, BaseCase Software, Germany Director of Licensing, MHRA, United Kingdom Director, Interdisciplinary Centre for Health Technology Assessment (HTA) and Public Health (IZPH), University of Erlangen-Nurnberg, Germany Director, Agency for Health Technology Assessment - AHTAPol, Poland Head of Health Technology Assessment, National Institute for Health and Clinical Excellence, United Kingdom Chair Health Economics, University of Leeds, United Kingdom Stephen McDonough, Senior Director Health Technology Assessment and Early Portfolio, UCB Pharma, Belgium Dr François Meyer, Director, Health Technology Assessment Division, Haute Autorit� de Sant�, France Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, United States Vice President, European Government Affairs & Head of Brussels Office, GlaxoSmithKline, Belgium Director of Health Technology Assessment, Health Inforamtion and Quality Authority (HIQA), Ireland HTA Director, CAHTA, Spain Mel Walker, Director Global Integrated Payer Strategy, GlaxoSmithKline, United Kingdom |
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
07/12/2010
|
|
|
|
|
|
|
|
Registration:
|
|
To register contact Sabrina on +44 (0)207 608 7055 or at skhamissa@healthnetworkcommunications.com Alternatively register online at https://secure.terrapinn.com/V5/rCalc.aspx?E=3581
|
|
|
E-mail:
|
|
skhamissa@healthnetworkcommunications.com
|
|
|
|
|
|
|
|
|